Related Experiment Video
Updated: Jan 25, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells
Baojie Zhang1, Bin Liu2, Deng Chen3
1Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. b.z.zhang@rug.nl.
Abstract:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered as a promising anti-cancer therapeutic. However, many cancers have been found to be or to become inherently resistant to TRAIL. A combination of epigenetic modifiers, such as histone deacetylase inhibitors (HDACi's), with TRAIL was effective to overcome TRAIL resistance in some cancers. Broad spectrum HDACi's, however, show considerable toxicity constraining clinical use. Since overexpression of class I histone deacetylase (HDAC) has been found in colon tumors relative to normal mucosa, we have focused on small spectrum HDACi's. We have now tested agonistic receptor-specific TRAIL variants rhTRAIL 4C7 and DHER in combination with several class I specific HDACi's on TRAIL-resistant colon cancer cells DLD-1 and WiDr. Our data show that TRAIL-mediated apoptosis is largely improved in WiDr cells by pre-incubation with Entinostat-a HDAC1, 2, and 3 inhibitor- and in DLD-1 cells by RGFP966-a HDAC3-specific inhibitor- or PCI34051-a HDAC8-specific inhibitor. We are the first to report that using RGFP966 or PCI34051 in combination with rhTRAIL 4C7 or DHER represents an effective cancer therapy. The intricate relation of HDACs and TRAIL-induced apoptosis was confirmed in cells by knockdown of HDAC1, 2, or 3 gene expression, which showed more early apoptotic cells upon adding rhTRAIL 4C7 or DHER. We observed that RGFP966 and PCI34051 increased DR4 expression after incubation on DLD-1 cells, while RGFP966 induced more DR5 expression on WiDr cells, indicating a different role for DR4 or DR5 in these combinations. At last, we show that combined treatment of RGFP966 with TRAIL variants (rhTRAIL 4C7/DHER) increases apoptosis on 3D tumor spheroid models.
Insights
Targeted histone deacetylase inhibitors (HDACi) combined with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants effectively overcome TRAIL resistance in colon cancer. This combination therapy shows promise for treating resistant colon cancers, including in 3D models.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential anti-cancer therapeutic but faces resistance in many cancers.
- Broad-spectrum histone deacetylase inhibitors (HDACi) show toxicity, limiting clinical application.
- Class I histone deacetylases (HDACs) are overexpressed in colon tumors, suggesting targeted inhibition as a strategy.
Purpose of the Study:
- To investigate the efficacy of combining specific class I HDAC inhibitors with TRAIL variants to overcome TRAIL resistance in colon cancer cells.
- To explore the role of specific HDACs (HDAC1, 2, 3, 8) in TRAIL-induced apoptosis.
- To evaluate the therapeutic potential of this combination in 3D tumor spheroid models.
Main Methods:
- Treatment of TRAIL-resistant colon cancer cell lines (DLD-1, WiDr) with specific class I HDAC inhibitors (Entinostat, RGFP966, PCI34051) and TRAIL variants (rhTRAIL 4C7, DHER).
- Assessment of apoptosis induction via TRAIL-mediated pathways.
- Gene silencing (knockdown) of HDAC1, 2, and 3 to confirm their roles.
- Analysis of death receptor (DR4, DR5) expression.
- Evaluation in 3D tumor spheroid models.
Main Results:
- Entinostat, RGFP966, or PCI34051 significantly enhanced TRAIL-induced apoptosis in WiDr and DLD-1 cells.
- HDAC1, 2, or 3 knockdown increased early apoptotic cells upon TRAIL variant treatment.
- RGFP966 and PCI34051 modulated DR4 and DR5 expression differently in DLD-1 and WiDr cells.
- Combined treatment of RGFP966 with TRAIL variants increased apoptosis in 3D tumor spheroid models.
Conclusions:
- Specific class I HDAC inhibitors (RGFP966, PCI34051) combined with TRAIL variants represent a novel and effective strategy against TRAIL-resistant colon cancer.
- Targeting HDAC3 or HDAC8, in particular, shows promise for enhancing TRAIL therapy.
- This combination therapy demonstrates efficacy in preclinical 3D models, warranting further investigation.
Related Concept Videos
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Histone Modification
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Histone Variants at the Centromere
Apoptosis
The Colonization of Land

